<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163446</url>
  </required_header>
  <id_info>
    <org_study_id>CF-301-102</org_study_id>
    <nct_id>NCT03163446</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients With Staphylococcus Aureus Bloodstream Infections (Bacteremia) Including Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ContraFect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ContraFect</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, efficacy and
      pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC)
      antibacterial therapy for the treatment of Staphylococcus aureus (S. aureus) bloodstream
      infections (bacteremia), including endocarditis in adults. Patients will be randomized to
      receive a single intravenous dose of CF-301 or placebo in addition to SOC antibacterial
      therapy. Patients will be prescribed standard of care antibiotics selected by the
      investigators based on their professional experience, practice guidelines and local
      antibiotic susceptibility information for the treatment of S. aureus bacteremia.

      CF-301 is a lysin and member of a new class of targeted protein-based antimicrobials that has
      demonstrated activity against S. aureus in laboratory (in vitro) and animal studies, alone
      and in addition to conventional antibiotics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events [Safety and Tolerability]</measure>
    <time_frame>Up to 28 days and up to 180 days</time_frame>
    <description>Description of incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcome at Day 14 (improvement, response, non-response)</measure>
    <time_frame>Day 14</time_frame>
    <description>Description of clinical outcome in the microbiological Intent-to-Treat (mITT) population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CF-301 Maximum plasma concentration (Cmax) and time to Cmax</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>CF-301 plasma concentrations at various time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CF-301 time to clearance</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>CF-301 plasma concentrations at various time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome at Day 7 (improvement, response, non-response)</measure>
    <time_frame>Day 7</time_frame>
    <description>Description of clinical outcome in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome at End of Standard of Care Therapy (EOT) (response, non-response)</measure>
    <time_frame>Between 28-42 days</time_frame>
    <description>Description of clinical outcome in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome at Test of Cure (TOC) (response, non-response)</measure>
    <time_frame>Between 56-70 days</time_frame>
    <description>Description of clinical outcome in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of bacteremia at Day 7 after CF-301/placebo administration</measure>
    <time_frame>Day 7</time_frame>
    <description>Number and percentage of patients with clearance of bacteremia in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of bacteremia at Day 14 after CF-301/placebo administration</measure>
    <time_frame>Day 14</time_frame>
    <description>Number and percentage of patients with clearance of bacteremia in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological eradication at end of standard-of-care antibacterial therapy (EOT)</measure>
    <time_frame>Between 28-42 days</time_frame>
    <description>Number and percentage of patients with microbiological eradication in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological eradication at test of cure (TOC)</measure>
    <time_frame>Between 56-70 days</time_frame>
    <description>Number and percentage of patients with microbiological eradication in the mITT population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Staphylococcus Aureus Bacteremia</condition>
  <condition>Staphylococcus Aureus Endocarditis</condition>
  <arm_group>
    <arm_group_label>CF-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CF-301</intervention_name>
    <description>CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion</description>
    <arm_group_label>CF-301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, given as a single 2 hour iv infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female, 18 years or older

          -  blood culture positive for S. aureus

          -  at least one sign or symptom attributable to S. aureus bacteremia

          -  known or suspected complicated S. aureus BSI and/or endocarditis by Modified Duke
             Criteria

          -  patient is not pregnant or breastfeeding and is not of reproductive potential or
             agrees to use contraception if of reproductive potential.

        Exclusion Criteria:

          -  patient previously received CF-301.

          -  treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for
             more than 72 hours within 7 days before randomization.

          -  presence of any removable infection source that will not be removed or debrided within
             72 hours after randomization.

          -  presence of infected prosthetic joint or presence of cardiac device

          -  brain abscess, osteomyelitis or meningitis.

          -  pneumonia or known polymicrobial bacteremia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director, ContraFect</last_name>
    <phone>914 207-2300</phone>
    <email>clinicalstudies@contrafect.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Head of Clinical Development Operations at ContraFect</last_name>
    <phone>914 207-2300</phone>
    <email>clinicalstudies@contrafect.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study Site</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF0301-102 Study Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301 Study Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study Site</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study Site</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF301-102 Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301 Study Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cf-301-102</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Vi√±a Del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Santa Rosita</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site</name>
      <address>
        <city>St. Pertersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CF-301-102 Study Site #2</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Guatemala</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>bacteremia</keyword>
  <keyword>staphylococcal endocarditis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

